Nigella Sativa: Pharmacological Insights and Bioactive Therapeutics

Introduction: Chronic inflammatory diseases, including obesity, diabetes, cancer, asthma, and cardiovascular disorders, remain major causes of global morbidity and mortality. Conventional Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are widely used but often cause serious adverse effects with long-term use. Nigella sativa (black cumin), a traditional medicinal plant, has been recognized for its diverse pharmacological properties, particularly its anti-inflammatory potential. Methods: A literature search was conducted in PubMed, Scopus, and Web of Science for peerreviewed articles and clinical studies published up to 2024. Studies reporting on phytochemical constituents, pharmacological activities, and mechanisms of action of Nigella sativa were analyzed. Results: Evidence indicates that Nigella sativa exhibits broad-spectrum pharmacological activities, including hepatoprotective, neuroprotective, gastroprotective, antioxidant, antimicrobial, and anticancer effects. Notably, its bioactive compound thymoquinone plays a central role in modulating inflammation, oxidative stress, immune responses, and metabolic regulation. Preclinical and limited clinical findings also suggest beneficial effects in asthma, diabetes, and cardiovascular health. Discussion: While findings support the therapeutic versatility of Nigella sativa, the majority of evidence is derived from experimental and preclinical models. Clinical data remain insufficient, highlighting the need for rigorous, large-scale human trials to validate efficacy and safety. Conclusion: Nigella sativa shows promise as a safe, multi-targeted natural anti-inflammatory agent. Its integration into modern therapeutics could offer novel alternatives for managing chronic inflammatory diseases, pending confirmation through high-quality clinical research.